Eli Lilly (NYSE:LLY) has been in the spotlight recently with a 3.96% share price increase over the past month. The selection ...

Eli Lilly (NYSE:LLY), a major pharmaceutical company listed on the S&P 500 and NYSE Composite, continues to attract attention ...

Eli Lilly and Company (NYSE:LLY) may offer a modest dividend yield, but its track record of consistent payouts remains strong ...

Shares of Verve Therapeutics, Inc. (VERV) rocketed 75% in pre-market on Tuesday after Eli Lilly and Company (LLY) announced ...

Deep-pocketed investors have adopted a bearish approach towards Eli Lilly (NYSE:LLY), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...

Eli Lilly (LLY) will acquire Verve Therapeutics (VERV) for up to $13.5/share, aiming to revolutionize cholesterol treatment.

Patients with obesity can now get Zepbound’s strongest doses for a flat rate through Lilly’s self-pay pharmacy.

The deal centers around a medicine that could “shift the treatment paradigm for cardiovascular disease,” Lilly said, but also ...

Eli Lilly is a global healthcare giant, generating strong growth from a diverse portfolio of blockbuster medications. Viking Therapeutics has a weight-loss drug candidate VK2735, that aims to compete ...

From a technical perspective, both stocks show strong bullish trends ... While both Novo Nordisk and Eli Lilly are poised to dominate the obesity-drug market, their strategic expansions into ...

Analyst Terence Flynn from Morgan Stanley maintained a Buy rating on Eli Lilly & Co ... recent prescription trends have shown promising results, with an increase in market share and total ...

Eli Lilly's Current Market Status With a volume of 324,237, the price of LLY is up 1.72% at $851.42. RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.